Skip to main content
SpringerLink
Log in

Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Electrophysiological evidence suggests a synergistic relationship between metabotropic (mGlu) and ionotropic (iGlu) glutamate receptors. The functional consequences of these interactions have not been investigated in neurodegenerative diseases such as in Parkinson’s disease.

Objective

The goals of this study are as follows: (1) to investigate the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and dizocilpine (MK-801), antagonists at metabotropic glutamate 5 (mGlu5) and NMDA receptors, respectively, on the akinetic syndrome observed in bilateral 6-OHDA-lesioned rats; (2) to investigate if the effects of MPEP were potentiated by co-treatment with a behaviorally inactive dose of MK-801; and (3) to investigate the effects of l-DOPA alone and in combination with MPEP on the akinetic syndrome observed in 6-OHDA-lesioned rats.

Methods

The effects of the different treatments (single and co-treatment) administered for 3 weeks were measured in 6-OHDA-lesioned rats trained to release a lever rapidly after a visual stimulus onset in a simple reaction time task.

Results

MPEP 0.75 mg/kg reversed the akinetic deficits produced by striatal dopamine depletion, while MPEP 0.375 mg/kg had no effect. Co-administration with MK-801 0.02 mg/kg, ineffective alone, failed to speed the recovery process of MPEP 0.75 mg/kg but revealed the anti-akinetic action of MPEP 0.375 mg/kg. l-DOPA 3 mg/kg alone had a potent anti-akinetic effect in 6-OHDA lesioned rats, and this effect was not potentiated by a subthreshold MPEP treatment.

Conclusion

These results support a critical role for mGlu5 receptor blockade in improving parkinsonian symptomatology either as a single treatment or in combination with low concentrations of l-DOPA and demonstrate an interaction between NMDA and mGluR5 in regulating these effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Amalric M, Koob GF (1987) Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats. J Neurosci 7:2129–2134

    Google Scholar 

  • Amalric M, Koob GF (1989) Dorsal pallidum as a functional motor output of the corpus striatum. Brain Res 483:389–394

    Article  Google Scholar 

  • Amalric M, Baunez C, Nieoullon A (1995a). Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behav Pharm 6:508–519

    Google Scholar 

  • Amalric M, Moukhles H, Nieoullon A, Daszuta A (1995b) Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 7:972–980

    Google Scholar 

  • Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, Sandberg M (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290:1393–1408

    Google Scholar 

  • Attucci S, Carla V, Mannaioni G, Moroni F (2001) Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 132:799–806

    Article  Google Scholar 

  • Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871–7879

    Google Scholar 

  • Benquet P, Gee CE, Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22:9679–9686

    CAS  PubMed  Google Scholar 

  • Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669–5678

    Google Scholar 

  • Breysse N, Amalric M, Salin P (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 23:8302–8309

    Google Scholar 

  • Brown VJ, Robbins TW (1991) Simple and choice reaction time performance following unilateral striatal dopamine depletion in the rat. Impaired motor readiness but preserved response preparation. Brain 114:513–525

    Google Scholar 

  • Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ (2004) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology Mar 13; [Epub ahead of print]

  • Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694–2706

    Google Scholar 

  • Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237

    Article  CAS  PubMed  Google Scholar 

  • Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies. Neurosci Biobehav Rev 21:455–468

    Article  Google Scholar 

  • DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281–285

    Article  CAS  PubMed  Google Scholar 

  • Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE (1997) (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265–267

    Article  Google Scholar 

  • Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493–1503

    Google Scholar 

  • Greenamyre JT, O’Brien CF (1991) N-methyl-d-aspartate antagonists in the treatment of Parkinson’s disease. Arch Neurol 48:977–981

    Google Scholar 

  • Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp Neurol 151:334–342

    Article  CAS  PubMed  Google Scholar 

  • Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199–1209

    Google Scholar 

  • Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004) Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29:1259–1269

    Google Scholar 

  • Javitch JA, Strittmatter SM, Snyder SH (1985) Differential visualization of dopamine and norepinephrine uptake sites in rat brain using. J Neurosci 5:1513–1521

    Google Scholar 

  • Kelsey JE, Mague SD, Pijanowski RS, Harris RC, Kleckner NW, Matthews RT (2004) NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology 175(2):179–188

    Article  Google Scholar 

  • Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116–123

    Article  Google Scholar 

  • Klockgether T, Turski L (1999) NMDA antagonists potentiate antiparkinsonian actions of l-dopa in monoamine-depleted rats. Ann Neurol 28(4):539–546

    Article  Google Scholar 

  • Kozela E, Pilc A, Popik P (2003) Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-d-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165:245–251

    Google Scholar 

  • Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132

    Article  Google Scholar 

  • Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001) Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21:5925–5934

    CAS  PubMed  Google Scholar 

  • Morelli M, Di Chiara G (1990) MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson’s disease. Eur J Pharmacol 182(3):611–612

    Article  Google Scholar 

  • Muller T, Benz S, Przuntek H (2000) Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 181:98–103

    Article  Google Scholar 

  • Mura A, Mintz M, Feldon J (2002) Behavioral and anatomical effects of long-term l-dihydroxyphenylalanine (l-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177:252–264

    Article  Google Scholar 

  • Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science 258:597–603

    Google Scholar 

  • Nakanishi S, Masu M (1994) Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 23:319–348

    Article  Google Scholar 

  • O’Leary DM, Movsesyan V, Vicini S, Faden AI (2000) Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 131(7):1429–1437

    CAS  PubMed  Google Scholar 

  • Ossowska K (1994) The role of excitatory amino acids in experimental models of Parkinson’s disease. J Neural Transm Parkinson’s Dis Dement Sect 8:39–71

    Google Scholar 

  • Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413–420

    Article  Google Scholar 

  • Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney

    Google Scholar 

  • Pisani A, Calabresi P, Centonze D, Bernardi G (1997) Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 120:1007–1014

    Google Scholar 

  • Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, Calabresi P (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 106:579–587

    Article  Google Scholar 

  • Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm Suppl 38:65–89

    Google Scholar 

  • Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1–R2

    Article  CAS  PubMed  Google Scholar 

  • Starr MS, Starr BS, Kaur S (1997) Stimulation of basal and l-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson’s disease. Neurosci Biobehav Rev 21:437–446

    Article  Google Scholar 

  • Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165–186

    Article  Google Scholar 

Download references

Acknowledgements

This research was supported by the ‘Centre National de la Recherche Scientifique’ and by the ‘Fondation de France’ (M.A). N.B. was supported by the ‘Fondation pour la Recherche Médicale’ and by ‘Institut Lilly’. The authors are grateful to Dr. Fabrizio Gasparini (Novartis Pharma AG, Basel, Switzerland) for the generous gift of MPEP and to Dr. C. Manrique for the help in iconography.

Author information

Authors and Affiliations

  1. CNRS and Université de Provence, Marseille, France

    Nathalie Turle-Lorenzo, Nathalie Breysse, Christelle Baunez & Marianne Amalric

Authors
  1. Nathalie Turle-Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Breysse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christelle Baunez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marianne Amalric
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne Amalric.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turle-Lorenzo, N., Breysse, N., Baunez, C. et al. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease. Psychopharmacology 179, 117–127 (2005). https://doi.org/10.1007/s00213-005-2202-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-005-2202-x

Keywords

Search

Navigation